News & Press

CordenPharma COVID-19 Customer Letter

May 28, 2020
COVID-19 > Read CEO Dr. Micheal Quirmbach's Customer Letter Response to COVID-19.

CordenPharma’s Weekly Update to COVID-19 (Novel Coronavirus)

Please Read CEO & President Dr. Michael Quirmbach’s Letter to Customers

Watch our COVID-19 Video Updates and Success Stories Here

Please click here to inform us of any urgent questions or concerns regarding COVID-19


Dear Valued Customer,

Due to the unfortunate global progression of COVID-19 (Novel Coronavirus) infections in March 2020, I instructed all CordenPharma employees and manufacturing facilities to cease and cancel all business travel and face-to-face meetings through the end of May, and to convert all scheduled meetings into video or teleconference calls. In addition, CordenPharma’s Corporate Compliance Team instructed our global network of facilities to reschedule all customer-related quality audits originally scheduled in Q2 of 2020, to take place in the second half of 2020.

I am glad to report that through the consistent efforts and hard work of all CordenPharma employees at the site level, we have experienced minimal disruptions to our regular operations. Our global facilities are working diligently to make additional capacity available that is particularly suited for COVID-19 treatment & vaccine development, such as the manufacturing of key APIs (e.g. Lipid Excipients) used for drug delivery formulations and Sterile Injectable Drug Product lines for the filling of new vaccines.

As the global attention slowly begins to turn towards the future, we are closely monitoring local government announcements regarding travel restrictions and border openings. Although our facilities will remain closed for visitations through the end of June 2020, we are working on the development of internal procedures as quickly as possible to allow for the safe reintroduction of site visits. We will inform you right away of any change to this information, and will follow up in June with a status update.

Rest assured that all CordenPharma employees, from the Executive Leadership Team to the Marketing & Sales Team, Facility Managing Directors and Operators, are aligned and committed to mitigating any impact on delivering your critical, often lifesaving, medications. We are doing everything possible on our end to support your patients through this crisis.

We appreciate your patience as we react to this global issue, and thank you for your ongoing support in returning to “business as usual” as quickly as possible. Feel free to reach out to your Key Account Managers or fill out this form with any questions or concerns.

I wish you and your families stay safe & healthy, as we continue to work together as a collective community to support business continuity and each other.

Best Regards,

Dr. Michael Quirmbach
Chief Executive Officer & President
CordenPharma